Allergan Pins Hopes on Millennials With Juvederm Marketing
It's all about the lips with the soon-to-be-acquired company's latest advertising push.
Allergan
AGN
AGN
$198.32
-$0.94
-0.5%
Price as of February 14, 2020, 4:15 p.m. EST
View Interactive AGN Charts
The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.
News & Analysis: Allergan
The Fool has written over 300 articles on Allergan.
With Solid Fourth Quarter Results, AbbVie Shows That Its Growth Days Are Far From Over
Despite Humira's declining international sales, AbbVie is still worth considering.
How Allergan Beat Estimates in What's Likely Its Last Quarterly Update
The drugmaker delivered solid top- and bottom-line improvement as it awaited the closing of its acquisition by AbbVie.
Allergan Reports Fourth-Quarter 2019 Results That Plow Past Expectations
The maker of Botox appears to be on an upswing just ahead of its megamerger with AbbVie.
AbbVie's Acquisition of Allergan Gets Help From Nestle and AstraZeneca
A pair of deals will remove some regulatory impediments to the merger.
Should You Buy Allergan Before the AbbVie Acquisition Closes?
The clock's ticking on this big pharmaceutical buyout.
Why AbbVie Stock Dipped in 2019
AbbVie's shares had an off year in 2019. Here's why.
Why AbbVie Could Be a Great Buy in 2020
The stock has already rallied 20% over the past three months, and with a new drug in the mix, it could continue to climb even higher.
AbbVie Lays Out Plans to Integrate Allergan
The company is leaving the aesthetics unit largely intact.
Is AbbVie's Stock a Buy?
The stock is trading near its 52-week high even though its returns are flat this year.
